Video on YouTube on LuViva, not sure the language.

According to FDA, Guided Therapeutics, Inc. Should Receive News During the Month of May, 2015 Regarding the PMA Amendment for LuViva; First Quarter 2015 Results and Conference Call on May 13th and May 14th, Respectfully.

Directly from Guided Therapeutics website:

First shipment to Indonesia - http://www.irdirect.net/pr/release/id/1227242

Wall Street Journal - Mar 16, 2015

http://www.wsj.com/articles/warning-prompts-shift-in-surgeries-on-women-1426549807?mod=e2tw

"But in November the U.S. Food and Drug Administration strengthened a warning it had given in April: that an estimated 1 in 350 women undergoing surgery to remove fibroids instead have a hard-to-detect cancer that can be spread by the tool, which typically employs a fast-rotating blade to cut tissue that is removed through small incisions."

The article's author also states at the bottom there is nothing that can detect 100% for sure or not if there is/are cancer cells.








I believe this acknowledgment and warning by the FDA coupled with the "Superbug" could have led and is still lending to the FDA delay - not wanting to spread cancers cells during and after the use of devices; as well as, the cleaning of the tools used.


LuViva sounds promising. Again, if the company can follow through and succeed is the question.

Here are some international articles on LuViva, I don't know if these have been posted on this board or not.

Canada: Feb - 21, 2015

http://thechronicleherald.ca/qe2times/research-innovation/1269826-new-scan-saves-time-during-colposcopy-procedures-for-women


Turkey: Feb - 15, 2015

http://www.memurlar.net/haber/501449/

You'll need to translate it, but when it starts talking about LuViva it states that there is only a 5% false positive/negative rate. With others, including smear, the false positive/negative rate is between 25-30%.




Now just if the company can follow through with their, so far, empty promises and extremely viable technology.

$ETRM - Company Update

http://ir.enteromedics.com/eventdetail.cfm?EventID=155056

http://ir.enteromedics.com/eventdetail.cfm?EventID=155056

Company Update

I am the same as you. I am currently in ETRM, I was just letting people know what I just found out.




In Reply:
I've seen some of Zacks rankings compared to other ranking and I've been truly confused on how they even came up with what they said. I don't put a lot of faith in them. That's just me tho.

ARN Alert
EnteroMedics Inc (NASDAQ:ETRM) was downgraded by Zacks from "outperform" to "neutral." $1.60 price target. Read more at http://www.analystratings.net/a/385604

EnteroMedics Inc (NASDAQ:ETRM) was downgraded by Zacks from "outperform" to "neutral." $1.60 price target.

Poorly written article on Seeking Alpha just appeared.


http://seekingalpha.com/article/2785275?source=iphoneportfolioapp_message


As of right now it is having little to no effect on the share price.

$CERS...It is jumping this morning as the FDA accepts the IDE for INTERCEPT

FDA ACCEPTS IDE SUPPLEMENT FOR INTERCEPT BLOOD SYSTEM TREATMENT OF EBOLA CONVALESCENT PLASMA

$CERS...It is jumping this morning as the FDA accepts the IDE for INTERCEPT

FDA ACCEPTS IDE SUPPLEMENT FOR INTERCEPT BLOOD SYSTEM TREATMENT OF EBOLA CONVALESCENT PLASMA

$CMRX...$CERS...Not sure if it has been discussed on this board, but Chimerix Inc. and Cerus Corp. were mentioned in an article on CNBC.com on November 18th, 2014.

Note: I do own $CERS.

Study will test survivors' blood to treat Ebola

ACST: The stock had a good day with a lot of volume. Shares traded were around 525K while the 10 day moving average is around 150K. The stock also reached a high of $1.00 before retracting to .957.

I am currently up around .50%.

Remember volume increases could me an increase in share price.

AEZS: Had good volume again today. The 10 day moving volume is around 570K shares trade and today the volume was 1.2M shares traded, this was more than double the average volume.

The stock finished $0.01 lower. I am still up around 3.5%.

Last week it did a similar move when it reached the 1.25 area - heavy volume, increase in share price, then a slight retrace.

Remember volume increases could me an increase in share price.

AEZS: Had a good appreciation in share price today. Stock went up around 4.7% today on late volume starting around 3PM. Volume ended at over 1.3M shares traded and the 10 day moving volume is around 550K shares traded.

I always look at an increase in share price with a significant increase in volume as a sign there could be more good things to come.

Currently I am up over 5% from my buy last friday.

Reply to:

PURCHASE: AEZS @ 1.26 in the Speculative Plays account.

Looking for possible information on the NDA for Macrilen as well a run up to the PDUFA during early November 2014.

Aeterna Zentaris Reports Second Quarter 2014 Financial and Operating Results

PURCHASE: ACST @ .95 in the Speculative Plays account.

Expecting this to run up to the end of September 2014.

Top line results from Phase II "TRIFECTA" Trial

SELL: 206 shares of POM from the Speculative Plays account for the proceeds of $5,564.24.



This money is the initial funding for the account. Remember this is a riskier account.

Welcome to Shizane's Wild World of BioTechs.

On this board I will track my trading success and failures.

This board will be filled with helpful news on the Healthcare sector, as well as other useful information.

I will be posting buys and sells of stocks, mutual funds and ETFs associated to the Healthcare sector. Most of these will be in the BioTech subcategory.

These are not recommendations to buy or sell any stock that appears on this page.

I also reserve the right to buy or sell any stocks, mutual funds or ETFs at my sole discretion.

Thanks for looking at the board and if you have any questions or comments don't be afraid to post on the board or send a private message.

UPDATE: 09/23/13

Updated the current share prices on the Stock Watchlist.

PURCHASE: IGXT

I purchased 1,000 shares of IGXT at .57 today.

Yes the stock is an OTC stock but it has a PDUFA date of February 3, 2013. Also the S-1 should be closed within the next week.

SOLD: ETRM

Sold ETRM at $1.23 from $1.20 entry.


The stock has been trading in a narrow range and I should having taken gains when it was trading in the $1.30's.

PURCHASE: ETRM

I purchased ETRM at a Cost Basis of $1.20 on 09/16/13.


Should be hearing about a possible ADCOM in the coming weeks.

SELL: PBMD

I sold PBMD @ $2.38 on 09/13/13 for an over 5% loss.

I have been unable to update the iHub Board; I will update more often.

PURCHASE: PBMD

Purchased PBMD @ 2.345 for a combined Cost Basis of 2.40.

I believe the stock should turn north soon. Result from CAN-103 is to be released on October 01, 2013.

SOLD: NVAX

Sold NVAX at $3.36 for a 2.36% gain will keep an eye on the stock as in nears the "Analyst Day" on September 24, 2013.

NEWS: NVAX - Currently Holding (updated)

NVAX - Currently Holding

Link for Novavax, Inc. Wedbush 2013 Life Sciences Management Access presentation on August 13, 2013 by president and CEO Stanley C. Erck.

NVAX Wedbush Presentation

NVAX - Currently Holding

Novavax, Inc. has a very interesting week.

Beginning on Wednesday, September 11, 2013 NVAX will present at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Denver, Colorado the session, entitled “RSV F Protein Vaccine Is Well-Tolerated and Immunogenic in Elders,” will present data from the company’s recently completed Phase 1 clinical trial of its RSV vaccine candidate in healthy elderly adults. Also, on the 11th “Passive Immunization with RSV F Vaccine-Induced Polyclonal Antibodies Protect Cotton Rats from RSV A Challenge" will be presented, both sessions are scheduled to be presented from 11:00AM - 01:00PM.

Then on Thursday, September 12, 2013 President and CEO of NVAX Stanley C. Erck will present at the Stifel Nicolaus Healthcare Conference 2013 in Boston, Massachusetts @ 09:45AM.


Links for more information on the presentations.
Novavax, Inc. Events

UPDATE: iBox - 09/09/13

Updated the Stock Watchlist with current 10-day moving average volumes and prices.

NEWS: CHTP

CHTP price target raised to $4.00 from $3.50 with a "buy" rating at Ladenburg Thalmann.

NEWS: NSTG, CGIX, TRGT, CEMI

NSTG

New Workflow to Provide Scientists with Tools That Enable Single Cell Analysis for Oncology, Immunology and Stem Cell Research

CGIX

Cancer Genetics, Inc. [CGIX] to Ring The NASDAQ Stock Market Opening Bell

Cancer Genetics Announces Exercise of Underwriters' Over-Allotment Option

TRGT

Targacept to Present at the Stifel Healthcare Conference 2013

CEMI

Form 8-K for CHEMBIO DIAGNOSTICS, INC.

UPDATE: 09/05/13

Updated the Stock Watchlist Current Prices

NEWS: APPY, RIGL

APPY

APPY Income Statement

Venaxis to Present at Three Upcoming Investor Conferences

RIGL

Rigel To Focus On ITP, DLE And Dry Eye

INFO: BioTech

Drug firms and cancer: Lucrative lifesavers

PURCHASE: NVAX

Added to a position in NVAX this morning at a Cost Basis of 3.30 a share for a combined Cost Basis of 3.25 a share for total NVAX holdings.

SOLD: MSTX

I sold the remaining MSTX shares I had at .4201 for a slight loss.

INFO: BioTech

It's No Accident That Drugs Are Expensive